Elizabeth Brickley
Concepts (341)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Zika Virus Infection | 52 | 2025 | 155 | 11.280 |
Why?
| Zika Virus | 40 | 2025 | 118 | 8.110 |
Why?
| Microcephaly | 30 | 2025 | 87 | 4.590 |
Why?
| Pregnancy Complications, Infectious | 27 | 2025 | 367 | 3.500 |
Why?
| Poliomyelitis | 9 | 2025 | 36 | 3.030 |
Why?
| Brazil | 50 | 2025 | 154 | 2.540 |
Why?
| Poliovirus Vaccine, Oral | 6 | 2025 | 25 | 2.340 |
Why?
| Poliovirus Vaccine, Inactivated | 6 | 2024 | 28 | 2.190 |
Why?
| Poliovirus | 6 | 2025 | 82 | 2.080 |
Why?
| Antibodies, Viral | 10 | 2025 | 601 | 1.580 |
Why?
| Arboviruses | 2 | 2022 | 13 | 1.570 |
Why?
| Dengue | 3 | 2022 | 69 | 1.410 |
Why?
| Immunity, Mucosal | 7 | 2025 | 94 | 1.370 |
Why?
| Malaria | 5 | 2019 | 59 | 1.330 |
Why?
| Leprosy | 7 | 2021 | 22 | 1.190 |
Why?
| Epidemics | 4 | 2021 | 81 | 1.170 |
Why?
| Anemia | 4 | 2019 | 160 | 1.130 |
Why?
| Immunoglobulin A | 8 | 2025 | 200 | 1.070 |
Why?
| Prenatal Exposure Delayed Effects | 10 | 2025 | 574 | 1.030 |
Why?
| Infant | 42 | 2025 | 8975 | 0.980 |
Why?
| Antibodies, Neutralizing | 9 | 2025 | 265 | 0.960 |
Why?
| Disease Outbreaks | 9 | 2024 | 349 | 0.960 |
Why?
| Vaccines, Attenuated | 3 | 2022 | 125 | 0.940 |
Why?
| Fetal Blood | 3 | 2017 | 317 | 0.940 |
Why?
| Pregnancy | 42 | 2025 | 6391 | 0.940 |
Why?
| Chikungunya Fever | 2 | 2024 | 76 | 0.940 |
Why?
| Virus Diseases | 3 | 2021 | 210 | 0.780 |
Why?
| Feces | 4 | 2022 | 441 | 0.770 |
Why?
| Chikungunya virus | 2 | 2024 | 76 | 0.770 |
Why?
| Arbovirus Infections | 1 | 2022 | 19 | 0.760 |
Why?
| Vaccines, Inactivated | 2 | 2019 | 68 | 0.750 |
Why?
| Child, Preschool | 36 | 2025 | 10459 | 0.750 |
Why?
| Cohort Studies | 24 | 2025 | 5409 | 0.730 |
Why?
| Mosquito Vectors | 2 | 2022 | 25 | 0.720 |
Why?
| Humans | 105 | 2025 | 129271 | 0.710 |
Why?
| Infant, Newborn | 30 | 2025 | 5736 | 0.690 |
Why?
| Malaria Vaccines | 2 | 2017 | 8 | 0.680 |
Why?
| Intestinal Mucosa | 3 | 2025 | 589 | 0.670 |
Why?
| Communicable Diseases, Emerging | 1 | 2020 | 32 | 0.670 |
Why?
| Workplace | 4 | 2024 | 247 | 0.630 |
Why?
| Pneumonia, Viral | 2 | 2020 | 339 | 0.610 |
Why?
| Coinfection | 1 | 2020 | 131 | 0.610 |
Why?
| Coronavirus Infections | 2 | 2020 | 333 | 0.610 |
Why?
| Female | 69 | 2025 | 68556 | 0.600 |
Why?
| Influenza Vaccines | 2 | 2019 | 532 | 0.560 |
Why?
| Socioeconomic Factors | 10 | 2023 | 1209 | 0.530 |
Why?
| Anopheles | 1 | 2016 | 14 | 0.530 |
Why?
| Malaria, Falciparum | 1 | 2016 | 26 | 0.530 |
Why?
| Hepcidins | 1 | 2016 | 22 | 0.520 |
Why?
| Vaccination | 6 | 2024 | 1347 | 0.520 |
Why?
| Fetal Diseases | 3 | 2021 | 158 | 0.460 |
Why?
| Iron | 1 | 2016 | 281 | 0.440 |
Why?
| Influenza, Human | 1 | 2019 | 601 | 0.420 |
Why?
| Pandemics | 2 | 2020 | 1482 | 0.410 |
Why?
| Male | 41 | 2025 | 63517 | 0.400 |
Why?
| Nervous System Malformations | 2 | 2023 | 37 | 0.390 |
Why?
| Cross-Sectional Studies | 11 | 2025 | 5051 | 0.390 |
Why?
| Immunoglobulin G | 6 | 2025 | 848 | 0.380 |
Why?
| Young Adult | 19 | 2025 | 12392 | 0.380 |
Why?
| Adult | 33 | 2025 | 35497 | 0.370 |
Why?
| Fetus | 2 | 2021 | 770 | 0.360 |
Why?
| Leprosy, Multibacillary | 2 | 2021 | 2 | 0.360 |
Why?
| Child | 25 | 2024 | 20785 | 0.360 |
Why?
| Exanthema | 2 | 2023 | 74 | 0.350 |
Why?
| Cryptorchidism | 2 | 2020 | 14 | 0.350 |
Why?
| Biomarkers | 5 | 2020 | 3968 | 0.310 |
Why?
| Poliovirus Vaccines | 2 | 2019 | 5 | 0.290 |
Why?
| Neurodevelopmental Disorders | 2 | 2020 | 155 | 0.290 |
Why?
| Adolescent | 16 | 2025 | 20315 | 0.280 |
Why?
| Virus Shedding | 4 | 2021 | 48 | 0.280 |
Why?
| Infant Mortality | 3 | 2024 | 103 | 0.280 |
Why?
| Maternal Exposure | 2 | 2021 | 177 | 0.280 |
Why?
| Urban Population | 2 | 2020 | 441 | 0.270 |
Why?
| Parturition | 3 | 2023 | 70 | 0.270 |
Why?
| Cytokines | 1 | 2014 | 2013 | 0.260 |
Why?
| Incidence | 9 | 2025 | 2636 | 0.260 |
Why?
| Prospective Studies | 13 | 2024 | 7123 | 0.260 |
Why?
| Immunoglobulin M | 4 | 2022 | 276 | 0.250 |
Why?
| Middle Aged | 17 | 2025 | 31091 | 0.240 |
Why?
| Adenoids | 2 | 2024 | 12 | 0.240 |
Why?
| Risk | 3 | 2020 | 854 | 0.240 |
Why?
| Respiratory Syncytial Viruses | 1 | 2025 | 52 | 0.230 |
Why?
| Case-Control Studies | 4 | 2021 | 3377 | 0.230 |
Why?
| Hearing Loss, Sensorineural | 1 | 2025 | 56 | 0.230 |
Why?
| Pharynx | 1 | 2024 | 58 | 0.230 |
Why?
| Language Development Disorders | 2 | 2022 | 46 | 0.220 |
Why?
| Prevalence | 6 | 2023 | 2554 | 0.220 |
Why?
| Hospitalization | 2 | 2025 | 2052 | 0.220 |
Why?
| Risk Factors | 12 | 2024 | 9746 | 0.220 |
Why?
| Pregnancy Outcome | 3 | 2021 | 389 | 0.210 |
Why?
| Transients and Migrants | 1 | 2023 | 25 | 0.210 |
Why?
| Americas | 2 | 2020 | 24 | 0.210 |
Why?
| Influenza A Virus, H1N1 Subtype | 1 | 2025 | 146 | 0.210 |
Why?
| Bayes Theorem | 2 | 2022 | 373 | 0.210 |
Why?
| Epilepsies, Partial | 2 | 2023 | 44 | 0.210 |
Why?
| Electroencephalography | 2 | 2023 | 399 | 0.210 |
Why?
| Meta-Analysis as Topic | 2 | 2021 | 170 | 0.210 |
Why?
| Belgium | 1 | 2022 | 12 | 0.200 |
Why?
| Smokers | 1 | 2023 | 138 | 0.200 |
Why?
| Respiratory Tract Infections | 2 | 2024 | 376 | 0.200 |
Why?
| Viruses, Unclassified | 1 | 2022 | 2 | 0.200 |
Why?
| United Kingdom | 2 | 2020 | 257 | 0.190 |
Why?
| Bronchoalveolar Lavage Fluid | 1 | 2025 | 644 | 0.190 |
Why?
| Urinary Tract | 1 | 2022 | 38 | 0.190 |
Why?
| Family Characteristics | 2 | 2020 | 178 | 0.190 |
Why?
| Hospital Records | 1 | 2021 | 11 | 0.190 |
Why?
| Hearing Loss | 1 | 2025 | 210 | 0.190 |
Why?
| Air Pollution | 1 | 2024 | 216 | 0.190 |
Why?
| Nervous System | 1 | 2022 | 67 | 0.190 |
Why?
| Child Mortality | 1 | 2021 | 13 | 0.190 |
Why?
| Epilepsy | 2 | 2023 | 322 | 0.190 |
Why?
| Serogroup | 2 | 2018 | 33 | 0.190 |
Why?
| Cerebral Palsy | 1 | 2023 | 96 | 0.180 |
Why?
| Orchiopexy | 1 | 2020 | 6 | 0.180 |
Why?
| Antibody Formation | 1 | 2022 | 291 | 0.180 |
Why?
| Control Groups | 1 | 2020 | 11 | 0.180 |
Why?
| Betacoronavirus | 2 | 2020 | 248 | 0.180 |
Why?
| Public Assistance | 1 | 2020 | 21 | 0.180 |
Why?
| Epidemiologic Research Design | 1 | 2020 | 27 | 0.180 |
Why?
| Language Development | 1 | 2021 | 64 | 0.180 |
Why?
| Endocrine System Diseases | 1 | 2020 | 33 | 0.170 |
Why?
| Air Pollutants | 1 | 2024 | 312 | 0.170 |
Why?
| Motor Skills | 1 | 2021 | 92 | 0.170 |
Why?
| Pregnancy, Twin | 1 | 2020 | 18 | 0.170 |
Why?
| England | 3 | 2024 | 72 | 0.170 |
Why?
| Viral Vaccines | 1 | 2021 | 94 | 0.170 |
Why?
| Central Nervous System Diseases | 1 | 2021 | 68 | 0.170 |
Why?
| Leprostatic Agents | 1 | 2020 | 5 | 0.170 |
Why?
| Breast Feeding | 1 | 2024 | 423 | 0.170 |
Why?
| Developing Countries | 2 | 2019 | 284 | 0.170 |
Why?
| Tanzania | 2 | 2019 | 44 | 0.170 |
Why?
| Tuberculosis | 1 | 2023 | 273 | 0.170 |
Why?
| Cross-Cultural Comparison | 1 | 2020 | 82 | 0.170 |
Why?
| Malformations of Cortical Development | 1 | 2020 | 13 | 0.170 |
Why?
| Plasmodium | 1 | 2019 | 13 | 0.170 |
Why?
| Cesarean Section | 1 | 2021 | 181 | 0.170 |
Why?
| Respiratory Sounds | 1 | 2020 | 118 | 0.160 |
Why?
| Coronavirus | 1 | 2020 | 43 | 0.160 |
Why?
| Protozoan Proteins | 2 | 2017 | 75 | 0.160 |
Why?
| Receptors, Complement 3b | 1 | 2019 | 84 | 0.160 |
Why?
| Hemagglutination Inhibition Tests | 1 | 2019 | 38 | 0.160 |
Why?
| Bangladesh | 1 | 2019 | 42 | 0.160 |
Why?
| Prenatal Diagnosis | 1 | 2021 | 190 | 0.160 |
Why?
| Administration, Intranasal | 1 | 2019 | 84 | 0.160 |
Why?
| Travel | 1 | 2020 | 121 | 0.160 |
Why?
| Disabled Persons | 1 | 2021 | 140 | 0.160 |
Why?
| Urbanization | 1 | 2019 | 27 | 0.160 |
Why?
| Influenza A Virus, H3N2 Subtype | 1 | 2019 | 43 | 0.160 |
Why?
| Infant, Newborn, Diseases | 1 | 2021 | 110 | 0.160 |
Why?
| Birth Certificates | 1 | 2019 | 10 | 0.160 |
Why?
| N-Acetylneuraminic Acid | 1 | 2019 | 11 | 0.160 |
Why?
| Death Certificates | 1 | 2019 | 29 | 0.160 |
Why?
| Intestines | 2 | 2021 | 347 | 0.160 |
Why?
| Esophageal Neoplasms | 1 | 2022 | 295 | 0.160 |
Why?
| Rural Population | 2 | 2021 | 513 | 0.150 |
Why?
| Chile | 1 | 2018 | 20 | 0.150 |
Why?
| Follow-Up Studies | 7 | 2023 | 4887 | 0.150 |
Why?
| Deglutition Disorders | 1 | 2020 | 134 | 0.150 |
Why?
| Comorbidity | 2 | 2020 | 1544 | 0.150 |
Why?
| Medical Record Linkage | 1 | 2019 | 60 | 0.150 |
Why?
| Developmental Disabilities | 1 | 2021 | 261 | 0.150 |
Why?
| Communicable Diseases | 1 | 2020 | 147 | 0.150 |
Why?
| Immunoglobulin D | 1 | 2018 | 29 | 0.150 |
Why?
| Spasms, Infantile | 1 | 2020 | 122 | 0.150 |
Why?
| Sporozoites | 1 | 2017 | 1 | 0.140 |
Why?
| Research | 1 | 2021 | 416 | 0.140 |
Why?
| Plasmodium falciparum | 1 | 2017 | 29 | 0.140 |
Why?
| Nervous System Diseases | 1 | 2020 | 252 | 0.140 |
Why?
| Rectus Abdominis | 1 | 2017 | 16 | 0.140 |
Why?
| Milk, Human | 1 | 2019 | 151 | 0.140 |
Why?
| Patient Participation | 1 | 2021 | 414 | 0.140 |
Why?
| Gestational Age | 4 | 2022 | 874 | 0.140 |
Why?
| Databases, Factual | 2 | 2021 | 1266 | 0.140 |
Why?
| Sepsis | 1 | 2023 | 572 | 0.130 |
Why?
| Esophageal Motility Disorders | 1 | 2016 | 26 | 0.130 |
Why?
| Endothelium | 1 | 2017 | 121 | 0.130 |
Why?
| Asthma | 2 | 2020 | 2229 | 0.130 |
Why?
| Arsenic | 1 | 2017 | 63 | 0.130 |
Why?
| Free Tissue Flaps | 1 | 2017 | 54 | 0.130 |
Why?
| Esophagitis | 1 | 2016 | 68 | 0.130 |
Why?
| Smoking | 1 | 2023 | 1499 | 0.130 |
Why?
| Social Determinants of Health | 1 | 2019 | 220 | 0.130 |
Why?
| Body Composition | 1 | 2019 | 649 | 0.120 |
Why?
| Adenocarcinoma | 1 | 2022 | 898 | 0.120 |
Why?
| Mammaplasty | 1 | 2017 | 98 | 0.120 |
Why?
| Deficiency Diseases | 1 | 2014 | 10 | 0.120 |
Why?
| Child Nutrition Disorders | 1 | 2014 | 19 | 0.120 |
Why?
| Wasting Syndrome | 1 | 2014 | 12 | 0.120 |
Why?
| Longitudinal Studies | 4 | 2023 | 2716 | 0.120 |
Why?
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2014 | 41 | 0.110 |
Why?
| Lymphocytes | 1 | 2016 | 378 | 0.110 |
Why?
| Pregnancy Complications | 1 | 2019 | 493 | 0.110 |
Why?
| Esophagus | 1 | 2016 | 248 | 0.110 |
Why?
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2014 | 86 | 0.110 |
Why?
| Tissue Donors | 1 | 2017 | 391 | 0.110 |
Why?
| Erythrocytes | 1 | 2019 | 673 | 0.110 |
Why?
| Dendritic Cells | 1 | 2017 | 479 | 0.110 |
Why?
| Cognition | 1 | 2021 | 1122 | 0.110 |
Why?
| Ecuador | 2 | 2024 | 8 | 0.100 |
Why?
| Interleukins | 1 | 2014 | 241 | 0.100 |
Why?
| Registries | 4 | 2022 | 1895 | 0.100 |
Why?
| Animals | 5 | 2022 | 35309 | 0.100 |
Why?
| Cause of Death | 2 | 2025 | 392 | 0.090 |
Why?
| Clinical Trials as Topic | 1 | 2016 | 1004 | 0.090 |
Why?
| Skin | 1 | 2016 | 726 | 0.090 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2017 | 857 | 0.090 |
Why?
| Diet | 1 | 2019 | 1212 | 0.090 |
Why?
| Feeding Behavior | 1 | 2016 | 622 | 0.090 |
Why?
| Interferon-gamma | 1 | 2014 | 772 | 0.090 |
Why?
| Occupational Exposure | 2 | 2024 | 299 | 0.090 |
Why?
| Neuroimaging | 2 | 2023 | 278 | 0.090 |
Why?
| Retrospective Studies | 4 | 2022 | 14461 | 0.090 |
Why?
| Growth Disorders | 2 | 2024 | 80 | 0.080 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2014 | 1202 | 0.080 |
Why?
| Infectious Disease Transmission, Vertical | 2 | 2021 | 170 | 0.080 |
Why?
| T-Lymphocytes | 1 | 2017 | 1933 | 0.080 |
Why?
| Latin America | 2 | 2020 | 87 | 0.080 |
Why?
| RNA, Viral | 2 | 2023 | 619 | 0.070 |
Why?
| Cerebral Cortex | 2 | 2023 | 436 | 0.070 |
Why?
| Polymerase Chain Reaction | 2 | 2020 | 1036 | 0.070 |
Why?
| Postoperative Complications | 1 | 2017 | 2473 | 0.060 |
Why?
| Surveys and Questionnaires | 3 | 2024 | 5384 | 0.060 |
Why?
| Serum | 1 | 2025 | 58 | 0.060 |
Why?
| Ventilation | 1 | 2024 | 40 | 0.060 |
Why?
| HIV Infections | 1 | 2019 | 2721 | 0.060 |
Why?
| Nasal Mucosa | 1 | 2024 | 107 | 0.050 |
Why?
| Manufacturing and Industrial Facilities | 1 | 2023 | 1 | 0.050 |
Why?
| Contact Tracing | 1 | 2023 | 23 | 0.050 |
Why?
| Alpha Rhythm | 1 | 2023 | 7 | 0.050 |
Why?
| Theta Rhythm | 1 | 2023 | 10 | 0.050 |
Why?
| Sleep Stages | 1 | 2023 | 45 | 0.050 |
Why?
| Health Status Indicators | 1 | 2024 | 167 | 0.050 |
Why?
| Plastics | 1 | 2023 | 47 | 0.050 |
Why?
| Information Storage and Retrieval | 1 | 2023 | 108 | 0.050 |
Why?
| Eye Movements | 1 | 2023 | 59 | 0.050 |
Why?
| DNA Viruses | 1 | 2022 | 11 | 0.050 |
Why?
| Spatio-Temporal Analysis | 1 | 2022 | 26 | 0.050 |
Why?
| Radionuclide Imaging | 1 | 2022 | 123 | 0.050 |
Why?
| Particulate Matter | 1 | 2024 | 246 | 0.050 |
Why?
| Wakefulness | 1 | 2023 | 120 | 0.050 |
Why?
| Urodynamics | 1 | 2022 | 35 | 0.050 |
Why?
| Treatment Outcome | 3 | 2022 | 10202 | 0.050 |
Why?
| Esophagectomy | 1 | 2022 | 125 | 0.050 |
Why?
| Age of Onset | 1 | 2023 | 496 | 0.050 |
Why?
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 108 | 0.050 |
Why?
| Evoked Potentials, Auditory | 1 | 2022 | 179 | 0.050 |
Why?
| Lithuania | 1 | 2021 | 1 | 0.050 |
Why?
| Parity | 1 | 2021 | 120 | 0.050 |
Why?
| Population Groups | 1 | 2021 | 60 | 0.050 |
Why?
| Carbon Dioxide | 1 | 2023 | 259 | 0.040 |
Why?
| Diagnostic Techniques, Surgical | 1 | 2020 | 2 | 0.040 |
Why?
| Caribbean Region | 1 | 2020 | 25 | 0.040 |
Why?
| Testicular Diseases | 1 | 2020 | 7 | 0.040 |
Why?
| Pregnancy, High-Risk | 1 | 2020 | 14 | 0.040 |
Why?
| Immunogenicity, Vaccine | 1 | 2021 | 27 | 0.040 |
Why?
| Infection Control | 1 | 2022 | 140 | 0.040 |
Why?
| Asymptomatic Infections | 1 | 2020 | 26 | 0.040 |
Why?
| Public Health Surveillance | 1 | 2020 | 68 | 0.040 |
Why?
| Delivery, Obstetric | 1 | 2021 | 136 | 0.040 |
Why?
| Hypertrophy | 1 | 2021 | 121 | 0.040 |
Why?
| Fetal Death | 1 | 2020 | 56 | 0.040 |
Why?
| Causality | 1 | 2020 | 118 | 0.040 |
Why?
| World Health Organization | 1 | 2020 | 110 | 0.040 |
Why?
| Neoadjuvant Therapy | 1 | 2022 | 381 | 0.040 |
Why?
| Maternal Age | 1 | 2020 | 124 | 0.040 |
Why?
| Treatment Adherence and Compliance | 1 | 2020 | 24 | 0.040 |
Why?
| Macaca fascicularis | 1 | 2019 | 62 | 0.040 |
Why?
| Clinical Laboratory Techniques | 1 | 2020 | 94 | 0.040 |
Why?
| Neutralization Tests | 1 | 2019 | 73 | 0.040 |
Why?
| Clinical Protocols | 1 | 2021 | 254 | 0.040 |
Why?
| Pregnant Women | 1 | 2020 | 114 | 0.040 |
Why?
| Infant, Low Birth Weight | 1 | 2020 | 135 | 0.040 |
Why?
| Symptom Assessment | 1 | 2020 | 125 | 0.040 |
Why?
| Seizures | 1 | 2023 | 401 | 0.040 |
Why?
| Cross Reactions | 1 | 2019 | 132 | 0.040 |
Why?
| Child Development | 1 | 2024 | 457 | 0.040 |
Why?
| Length of Stay | 1 | 2025 | 1120 | 0.040 |
Why?
| Macaca mulatta | 1 | 2019 | 149 | 0.040 |
Why?
| Kaplan-Meier Estimate | 1 | 2021 | 851 | 0.040 |
Why?
| Maternal Death | 1 | 2019 | 11 | 0.040 |
Why?
| Maternal Mortality | 1 | 2019 | 40 | 0.040 |
Why?
| Cities | 1 | 2019 | 105 | 0.040 |
Why?
| Live Birth | 1 | 2019 | 57 | 0.040 |
Why?
| Global Health | 1 | 2021 | 327 | 0.040 |
Why?
| Mosquito Control | 1 | 2019 | 27 | 0.040 |
Why?
| Stillbirth | 1 | 2019 | 60 | 0.040 |
Why?
| Uterus | 1 | 2020 | 207 | 0.040 |
Why?
| Educational Status | 1 | 2021 | 469 | 0.040 |
Why?
| Birth Weight | 1 | 2022 | 505 | 0.040 |
Why?
| CD4 Lymphocyte Count | 1 | 2019 | 266 | 0.040 |
Why?
| Species Specificity | 1 | 2019 | 574 | 0.040 |
Why?
| Capacity Building | 1 | 2019 | 59 | 0.040 |
Why?
| Health Services Needs and Demand | 1 | 2020 | 263 | 0.040 |
Why?
| Congenital Abnormalities | 1 | 2019 | 74 | 0.040 |
Why?
| Odds Ratio | 1 | 2021 | 1019 | 0.040 |
Why?
| Ultrasonography, Prenatal | 1 | 2020 | 270 | 0.040 |
Why?
| Mali | 1 | 2017 | 3 | 0.040 |
Why?
| Anticonvulsants | 1 | 2020 | 209 | 0.040 |
Why?
| United States | 2 | 2025 | 13828 | 0.040 |
Why?
| Antibodies, Protozoan | 1 | 2017 | 32 | 0.040 |
Why?
| CD8 Antigens | 1 | 2017 | 76 | 0.040 |
Why?
| Inflammation | 2 | 2019 | 2737 | 0.030 |
Why?
| New Hampshire | 1 | 2017 | 4 | 0.030 |
Why?
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2017 | 100 | 0.030 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 833 | 0.030 |
Why?
| Biomedical Research | 1 | 2023 | 637 | 0.030 |
Why?
| Immunity | 1 | 2017 | 138 | 0.030 |
Why?
| Prenatal Care | 1 | 2019 | 274 | 0.030 |
Why?
| Lymphocyte Count | 1 | 2016 | 148 | 0.030 |
Why?
| Mastectomy | 1 | 2017 | 131 | 0.030 |
Why?
| Population Surveillance | 1 | 2019 | 438 | 0.030 |
Why?
| Body Weight | 1 | 2019 | 939 | 0.030 |
Why?
| Immunization Schedule | 1 | 2016 | 197 | 0.030 |
Why?
| Aged | 2 | 2024 | 22032 | 0.030 |
Why?
| Africa South of the Sahara | 1 | 2014 | 41 | 0.030 |
Why?
| Mothers | 1 | 2020 | 730 | 0.030 |
Why?
| Graft Survival | 1 | 2017 | 511 | 0.030 |
Why?
| Qualitative Research | 1 | 2021 | 1215 | 0.030 |
Why?
| Observational Studies as Topic | 1 | 2014 | 110 | 0.030 |
Why?
| Placenta | 1 | 2020 | 723 | 0.030 |
Why?
| Peptide Fragments | 1 | 2017 | 692 | 0.030 |
Why?
| Drug Therapy, Combination | 1 | 2016 | 1040 | 0.030 |
Why?
| Research Design | 1 | 2019 | 1043 | 0.030 |
Why?
| Biopsy | 1 | 2016 | 1092 | 0.030 |
Why?
| Age Factors | 1 | 2020 | 3140 | 0.030 |
Why?
| Mass Screening | 1 | 2020 | 1149 | 0.020 |
Why?
| Algorithms | 1 | 2019 | 1613 | 0.020 |
Why?
| Health Services Accessibility | 1 | 2019 | 899 | 0.020 |
Why?
| Logistic Models | 1 | 2016 | 1985 | 0.020 |
Why?
| Body Mass Index | 1 | 2019 | 2272 | 0.020 |
Why?
| Tomography, X-Ray Computed | 1 | 2020 | 2515 | 0.020 |
Why?
| Cell Proliferation | 1 | 2017 | 2375 | 0.020 |
Why?
| Cells, Cultured | 1 | 2017 | 4077 | 0.020 |
Why?
| Liver | 1 | 2017 | 1839 | 0.020 |
Why?
| Disease Progression | 1 | 2016 | 2630 | 0.020 |
Why?
| Home Care Services | 1 | 1971 | 225 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2020 | 3386 | 0.020 |
Why?
| Disease Models, Animal | 1 | 2017 | 4057 | 0.020 |
Why?
| Medicare | 1 | 1971 | 706 | 0.020 |
Why?
| Mice | 1 | 2017 | 16915 | 0.010 |
Why?
| Nebraska | 1 | 1971 | 10 | 0.010 |
Why?
|
|
Brickley's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|